Switching to DTG/3TC or continuing B/F/TAF tied to similar virologic efficacy in adults with HIV
04 Dec 2025
byElaine Soliven
Switching to dolutegravir/lamivudine (DTG/3TC) or continuing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) showed comparable virologic efficacy through 96 weeks in adults with HIV infection, according to the DYAD observational, open-label extension (OLE) study presented at IDWeek 2025.